Korea University Anam Hospital
Seoul, Seongbuk-gu, 02841, South Korea
NCT Number: NCT07342387
1. Background Value of Sweat: Sweat has gained significant attention as a key biomarker for diagnosing dehydration and renal dysfunction (e.g., uremia), as it contains essential indicators that reflect blood concentrations, such as electrolytes and metabolites (creatinine, urea).
Technical Transition: To overcome the limitations of conventional absorbent pads, such as contamination and evaporation, it is essential to develop flexible, wearable microfluidic devices that enable immediate collection and high-precision analysis.
Domestic and International Trends: While countries like the U.S. are already utilizing real-time IoT monitoring technologies in military and sports sectors, there is an urgent need in Korea to secure physiological data optimized for the Korean population and to establish a robust medical analysis system.
2. Objectives To develop a skin-interfaced microfluidic platform integrated with a SERS biosensor for high-sensitivity, real-time detection of Sodium and Creatinine to monitor dehydration and renal health.
3. Research Plan
1. Subject Selection: Recruit and obtain informed consent from patients visiting the hospital with renal disease (creatinine levels 1.5 mg/dL or higher). 2. Clinical Schedule: Conduct the clinical study on the subjects' scheduled routine blood test dates. 3. Patch Attachment: Apply the sweat collection patch and a control absorption pad to 1-2 body areas (e.g., center of the chest, forehead). 4. Sweat Induction: Induce sweating by having subjects wait in an electric thermal chamber for 30 minutes. 5. Absorption Pad Collection: For the control pads (which cannot collect time-series data), attach two initially and retrieve them during the early stages of sweat secretion. 6. Microfluidic Patch Collection: Measure the volume of sweat collected (~100 uL per subject) to calculate sweat loss, then seal and transport to the laboratory. 7. Comparative Sample Processing: Measure the weight of absorption pads before/after use to determine fluid loss. Extract sweat samples (~500 uL per subject) into micro-tubes for transport. 8. Contamination Control: Utilize dry ice and insulated coolers during transport to prevent sample degradation or contamination. 9. Quantitative Analysis & Evaluation: Perform quantitative analysis of sodium and creatinine levels from both samples using the proposed SERS-based method and standard analytical tools (HPLC or LC-MS). Compare the changes in biomarkers and sweat loss over time to evaluate and summarize the hydration status and renal function patterns of each subject.
Looking for future studies?
Notify Me19 year and older
All sexes
Interventional
Not applicable
Seoul, Seongbuk-gu, 02841, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time-course changes in Sodium and Creatinine levels.
Time frame: enrollment day
Measurement on the day of enrollment (Visit 1), followed by study termination
Korea University
Other
Development of Microfluidic Patch-type Sweat Sensor Utilizing Surface-enhanced Raman Mechanism
Acronym: sweat sensor
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05013944
Certain Conditions Originating in the Perinatal Period, Chemically-Induced Disorders
Arlington Heights, Illinois, United States
View Trial DetailsNCT07343388
Emergence Delirium in Pediatric Anesthesia, Neurologic Manifestations
Izmir, Konak, Turkey (Türkiye)
View Trial DetailsNCT06805149
Calculi, Female Urogenital Diseases
Helsingborg, Sweden
View Trial DetailsNCT00004448
Autoimmune Diseases, Disease Attributes
Dallas, Texas, United States
View Trial Details